Main > ONCOLOGY (**) > Breast Cancer>HR+>HER2->MET *** > Treatment > USA. P. Palbociclib+
USA. P. Palbociclib+'s subsections
(*) USA Approval Date: 2015. 02.03
(**) USA Approval Date: 2017. 04.03
(**) USA Approval Date: 2019. 04.05
+Aromatase Inhibitor (**)
+Letrozole (*)
Company
EGF: Epidermal Growth Factor
HER: Human EGF Receptor
HR: Hormone Receptor
Patent>Assignee; Claims; No.; Etc.
Patent>Expiration: 2027. 03
Patent>UpDate: 2016. 08.23.
TradeMark
TradeMark Web-Site
USA. P. Palbociclib+'s products
This section has no products